Interference of a propranolol metabolite with serum bilirubin estimation in chronic renal failure Some patients with chronic renal failure have shown consistently raised serum bilirubin concentrations, as measured by an automated diazo technique (SMA 12/60, Technicon Instruments). Hyperbilirubinaemia, however, was not detected with the Bilirubinometer (British American Optical Company), which uses a direct photometric technique rather than a chemical reaction. Since all of these patients had been given antihypertensive agents, we have investigated the possibility that this interference with the diazo reaction (which we have called "false bilirubin") was due to retention of a drug in chronic renal failure. IU/l and alkaline phosphatase activity under 130 IU/1), and serum creatinine concentrations over 400 tLmol/l (4-5 mg/100 ml). There were 21 such patients (table). All were suffering from chronic renal failure, and all but three were taking propranolol.
Stored, frozen sera obtained from 13 of the 21 patients, including two of the three patients not receiving propranolol, were retested using a diazo technique,' and by the Bilirubinometer. All but one of the sera from patients taking propranolol showed abnormal diazo reactions and normal Bilirubinometer results, indicating the presence of "false bilirubin." The samples from the two patients who were not taking propranolol showed raised bilirubin concentrations when tested with both the Bilirubinometer and the diazo reaction. They therefore had true hyperbilirubinaemia. Thus all the patients with "false bilirubin" were taking propranolol.
We used 15 consecutive patients with chronic renal failure who were neither undergoing dialysis nor receiving propranolol as control subjects. Study of the case notes of these patients showed that they had never had hyperbilirubinaemia (diazo technique, data available from authors on request). The report by Andrewes2 of false-positive diazo reactions in uraemic sera almost certainly referred to patients who were more uraemic and had a more active catabolism than ours.
Serial studies on several patients receiving a constant dose of propranolol showed that there was a relation between the "false bilirubin" concentration and the serum creatinine concentration. When haemodialysis was started the "false bilirubin" values fell, despite the continued administration of propranolol. Peritoneal dialysis did not seem as effective in removing this substance.
The table shows that 13 of the 21 patients were taking hydralazine. We found, however, that neither hydralazine itself nor eight known metabolites interfered with the diazo reaction. We also found that propranolol itself did not interfere with the diazo reaction, but that two of its metabolites, 4-hydroxypropranolol and 1-naphthol, gave false-positive results. 4-Hydroxypropranolol is a major hepatic metabolite of propranolol and is excreted in the urine as glucuronide and sulphate conjugates.3 Several serum samples from our patients were treated with glucuronidase and sulphatase, which deconjugate these compounds, and were examined by two-dimensional thin-layer chromatography. This showed that the substance in these sera that reacted with the diazo reagent had, after deconjugation, identical chromatographic properties to 4-hydroxypropranolol.
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Comment
We have shown that a propranolol metabolite, a conjugate of 4-hydroxypropranolol that is normally excreted in the urine,. accumulates in the plasma of undialysed patients with chronic renal failure and interferes with the widely used diazo reaction to give falsely raised bilirubin concentrations, which may cause confusion clinically and lead to unnecessary investigations. The Bilirubinometer, available in most neonatal units, provides a simple way of avoiding this source of error.
